ArticleNature biotechnology2016
The emerging patent landscape of CRISPR-Cas gene editing technology.
Article in Nature biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- An Analysis of the Governance, Ethical, Legal, and Social Implications of Biocomputing.Science and engineering ethics · 2026Article
- TTLOC: A Tn5 transposase-based approach to localize T-DNA integration sites.Plant physiology · 2025Article
- CRISPR/Cas9 Technology for Enhancing Desirable Traits of Fish Species in Aquaculture.International journal of molecular sciences · 2024Review
- Review
- Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine.Animals : an open access journal from MDPI · 2023Review
- Points to consider in the development of national human genome editing policy.Cambridge prisms. Precision medicine · 2023Review
- Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications.World journal of clinical cases · 2022Review
- The Emergence of Genome Editing-Innovation Network Dynamics of Academic Publications, Patents, and Business Activities.Frontiers in bioengineering and biotechnology · 2022Article
- Assessing environmental impact of genetically modified seeds in Brazilian agriculture.Frontiers in bioengineering and biotechnology · 2022Article
- Should Gene Editing Be Used to Develop Crops for Continuous-Living-Cover Agriculture? A Multi-Sector Stakeholder Assessment Using a Cooperative Governance Approach.Frontiers in bioengineering and biotechnology · 2022Article
- Comparison of public discussions of gene editing on social media between the United States and China.PloS one · 2022Article
- Governance Choices of Genome Editing Patents.Frontiers in political science · 2021Article
- The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape.Nature biotechnology · 2020Article
- Article
- Review
- Art-Science Collaboration in an EPSRC/BBSRC-Funded Synthetic Biology UK Research Centre.Nanoethics · 2020Article
- Access and openness in biotechnology research collaborations between universities and industry.Nature biotechnology · 2019Article
- Worldwide CRISPR patent landscape shows strong geographical biases.Nature biotechnology · 2019Article
- Provenance and risk in transfer of biological materials.PLoS biology · 2018Article
- Patent mining and landscaping of emerging recombinant factor VIII through network analysis.Nature biotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27727218What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.